Company will take aim at ophthalmic and diabetes-related indications.

Pipex Pharmaceuticals expanded its existing flupirtine license agreement with McLean Hospital to cover the use of oral flupirtine for the treatment of a range of ophthalmic and diabetes-related indications. Pipex already has rights to use the molecule for the treatment of fibromyalgia; Effirma is currently in Phase II development.

The potential therapeutic indications covered by the additional intellectual property include glaucoma, age-related macular degeneration, retinitis pigmentosa, diabetic maculopathy, and diabetic retinopathy.

Oral flupirtine, a nonopiate analgesic, has been approved in Europe since 1984 as a treatment for pain. It has been used by approximately 1.5 million European patients for more than 25 years for treatment of post-surgical pain, cancer pain, trauma pain, pain associated with liver disease, and other nocioceptive pain states, according to the company. Flupirtine, however, has never been approved for any indication in the U.S.

Previous articleBAC to Develop Custom Ligand to Purify LFB and GTC’s Recombinant Factor VIIa
Next articleManner of Regulation Affects Estrogen Receptor Response